| INTRODUCTION
Pain syndromes in dogs are challenging to identify and manage because of the difficulty of inferring behaviors in dogs. Veterinarians must rely on owner observations and physical examination findings to assess the efficacy of treatments, and frequently a mismatch is present in these observations. Specifically, Chiari-like malformation and syringomyelia (CMSM) is a disease complex that causes a neuropathic pain syndrome in Cavalier King Charles Spaniels (CKCS). This condition arises from a congenital malformation that results in a relatively small caudal fossa with respect to the brain causing crowding of the cerebellum and brainstem. [1] [2] [3] [4] [5] [6] [7] Many CKCS with CM also develop
Abbreviations: CKCS, Cavalier King Charles Spaniels; CM, Chiari-like malformation; CM1, Chiari-type 1 malformation; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; NCSU, North Carolina University; QST, quantitative sensory testing; SM, syringomyelia syrinxes within the spinal cord (syringomyelia, SM) because of disruption of cerebrospinal fluid (CSF) flow. Commonly, owners of affected CKCS report signs of phantom scratching, crying out in pain, rubbing of the face and ears, pain on defecation, reluctance to play, collar sensitivity, and aversion to being touched on the head, 8 and these signs are thought to result from SM disrupting sensory pathways. [9] [10] [11] Chiari-type 1 malformation (CM1) in humans is similar to CMSM in CKCS and involves descent of the cerebellum and brainstem through the foramen magnum. Chiari-type 1 malformation in humans also is commonly associated with the development of SM, with an estimated 65%-80% of patients developing both conditions. 12, 13 People with CM1 describe a wide range of signs including numbness, neck pain, headaches, memory loss, aphasia, and even depression. 14 Pain and sensory deficits in human CM1 patients have been quantified using thermal and mechanical sensory testing, and patient drawn pain maps. [14] [15] [16] [17] Thermohypoesthesia and decreased sensory perception are common findings in people with CM1 and SM, 1, 15 but the presence of pain in human patients clearly indicates that sensory changes can involve both gain as well as loss of function. Although the majority of outcome assessments in people with neuropathic pain rely on the patient's description of sensations based on questionnaires or phone call follow-ups, the use of quantitative sensory testing (QST; thermal and mechanical) has been validated using test-retest and interobserver reliability. 18 Furthermore, 1 study indicated that the duration of sensory deficits quantified by QST before surgery was the best predictor of surgical outcome in patients with SM. 
| Magnetic resonance imaging protocol
All dogs underwent MRI of the brain and cervical spinal cord using a 
| Statistical analysis
All analyses were performed using JMP software (JMP Pro 12.2.0, SAS Version 9.4, Cary, North Carolina). Summary statistics were generated on the presence of SM, maximum SM diameter, presence of owner-reported signs, bilateral thermal latencies and mechanical thresholds, and response rates at each site tested. A Shapiro-Wilk test was used to assess normality of continuous data. Mean and SD calculations were reported for normally distributed data. Otherwise, median and range were reported. The relationship between sensory thresholds (latencies and response rates) and the presence (categorized as yes or no) and severity of SM (quantified by maximum SM diameter) was examined. In addition, latencies and response rates were compared with owner-reported signs, (symptomatic versus asymptomatic), and the presence of pain on neurological examination (yes or no). Wilcoxon rank sum tests were used when latencies and thresholds were compared with categorical data. Linear regression was used to model the relationship between continuous variables. All binary categorical data were compared using contingency tables and chi-square tests for association with Fisher's exact tests used when there were <5 observations in a category. The Benjamini-Hochberg procedure was used to correct for multiple comparisons. A P value of <.05 was considered statistically significant.
| RESULTS
Fifty-six dogs were enrolled. Owner participation was voluntary, and therefore, the population was not considered random. The age range of dogs included in the study was 15 months to 11 years. There were 12 females, 16 spayed females, 8 males, and 20 neutered males. One patient had an adverse skin reaction during thermal testing (hyperemia) and was removed from the study. Another patient was removed Table 1 .
| Magnetic resonance imaging findings

| Sensory thresholds
Thermal latencies were measured in 32 dogs and 44 dogs underwent mechanical testing. Feasibility scores are reported in 
| DISCUSSION
In our study, we performed QST using mechanical (n = 44) and thermal (n = 32, hot and cold) stimuli in a cohort of CKCS. Currently, no information is available on quantified sensory dysfunction comparing CKCS with and without CMSM. Our results showed no significant difference in latencies, thresholds or response rates, thermal or mechanical, in dogs with and without SM or in dogs that were owner-reported symptomatic versus asymptomatic but did show a correlation of mechanical thresholds to neurological examination findings.
Quantitative sensory testing has been used extensively in human CM1 patients and the results display a complicated mix of paresthesias, anesthesia, and allodynia. In 1 study, CM1 patients described an increase in number and area of painful sites on pain drawings but also experienced thermohypoesthesia of the face and body. 17 Another study found that both SM and CM1 patients had anesthesia to heat and cold as well as vibration deficits that were of greater magnitude in the CM1 patients. 15 An important distinction regarding the use of QST in people and dogs is the interpretation of the response. In humans, detection thresholds for the stimulus and the pain threshold for the same stimulus can be differentiated clearly by the subject. This is much more difficult to do in dogs. The behaviors we used to determine threshold were more likely to represent a response to a noxious stimulus but could simply mean the stimulus was perceived. All dogs were tested in the same way and we have not attempted to differentiate between perception and noxious thresholds.
The behaviors reported by owners of dogs with CMSM suggest that the dogs could be more sensitive to stimuli. However, the possibility that they have hypoesthesia (decreased sensitivity) is much harder to determine from their behavior. Furthermore, it may be the case that some dogs show decreased sensitivity whereas others show increased sensitivity or perhaps within a dog there may be bidirectional sensory changes (thermohypoesthesia and mechanical hyperalgesia) as seen in human medical literature. These complexities could explain the lack of associations found in our study. Indeed, the difficulty in interpreting behavioral responses both makes it challenging to understand the pathophysiology of the disease and to assess the efficacy of therapies for this disease. Currently, the use of owner assessments, collecting a detailed history, and physical and neurological examinations are used to monitor CKCS with CMSM. We attempted to collect QST data as a continuous measure of sensory dysfunction to complement our current, broader scales for pain.
Quantitative sensory testing has been used in dogs including studies in research colonies of beagles 27, 28 as well as client-owned healthy dogs 31 and in those with osteoarthritis 25, 29 and spinal cord injury. 24, 32 Various QST modalities (thermal and mechanical) have been employed in previous work. Mechanical stimuli include touch, pressure, and vibration, and the information is transmitted through mechanoreceptors in the skin and travels along myelinated axons through the dorsal columnmedial lemniscal pathway. Commonly, von Frey filaments have been used in humans with SM 15, 16 and in various studies of pain in dogs. 23, [25] [26] [27] [28] [29] 32, 33 The use of von Frey mechanical testing has been found to be feasible and reliable 31, 33 and in 1 study identified different thresholds in normal dogs compared to dogs with acute spinal cord injury. 32 However, a lack of association between normal dogs and dogs with chronic pain also has been noted using von Frey techniques. 23 Additionally, vibration testing is used in humans with SM 15 and neuropathic pain, as another form of mechanical stimulation. 34 No data have been reported on vibration testing in dogs and this approach may be considered for future work. In our study, mechanical testing was performed using specialized calibrated hemostatic forceps used in our laboratory previously. 24 These forceps were developed to evaluate skin sensation after the administration of peripheral nerve blocks. 30 This method was chosen based on ease of use at novel testing sites in the neck. A drawback of this technique, as for any mechanical testing technique, is variability in rate of application of pressure delivered by the Thermal testing also has been used in humans [15] [16] [17] 35 and dogs [23] [24] [25] [26] 29 to evaluate neuropathic and chronic pain. Temperature and pain stimuli are carried by nonmyelinated C fibers through the spinothalamic pathway. A lightbox model (Canine Thermal Escape Model) has been used that allows latency to heat to be quantified by measuring the time taken for a dog to move its paw away from a light beam directed at the ventral surface of the paw. 29 Given our desire to test specific dermatome regions, the thermal probe allowed testing of regions pertinent to CKCS with CMSM. Previously established temperatures and maximum duration for testing was determined by 1 of the authors (Duncan Lascelles). Using these methods, we were able to minimize skin irritation, with only 1 dog exhibiting sensitivity to the thermal probe.
Adapting previously described protocols, testing locations for each sensory modality were selected based on clinical signs of CMSM in dogs, neuroanatomy of sensory dermatomes and feasibility in pet dogs. The locations tested were determined by extensive trial and error during development of the protocols and were based on the ability to gather reliable data. Human CM1 patients describe sensory abnormalities affecting the upper extremities and head and neck region. Most commonly, owners of affected CKCS report signs in similar areas including the shoulder, head, and neck regions. Furthermore, CKCS with SM frequently have both cervical and thoracic involvement. Given this information, our testing sites (neck, humerus, and thorax) were located in dermatomes associated with syrinx location.
Despite our carefully devised protocol, we found no association between SM and sensory dysfunction. Clearly, SM location along the spinal cord could impact the distribution of hyperesthesia or hypoesthesia, and perhaps sensory testing should be tailored for each individual dog. Because the location of SM can differ among dogs, it is difficult to generate a feasible, reliable sensory testing protocol suitable for all CKCS with SM. Nonetheless, these findings are in agreement with our detailed questionnaire analysis of owner-reported signs in CKCS in the same population of dogs, where it was concluded that the presence of scratching and pain per owner were not associated with SM. 8 The lack of association between SM and sensory dysfunction may highlight the difficulty in deciphering canine behavior using these protocols. Nonetheless, our feasibility scores demonstrated testing was performed with no difficulty or mild difficulty in 76% of the dogs tested. Poor feasibility scores were rare (n = 5) and were attributed to external distractions, anxiety, or reluctance to be restrained. Another potential pitfall of this work was the number of dogs on medications during the trial. Owners were asked to withdraw medications before testing, but some owners were reluctant to do so because of the severity of their dogs' signs. All of these dogs were reported to be symptomatic while on their medications, but the analgesic drugs they were receiving could have altered the results of the QST. In addition, because of our small sample size (n = 44 for mechanical, n = 32 for thermal) with only 14 CKCS without SM, we may not have had adequate study power to detect differences among groups. We anticipate that these data can be used in future studies to estimate appropriate group sizes. Lastly, we recognize that hyperesthesia could have been caused by coat clipping before thermal testing in some dogs, potentially increasing variability in thermal latencies. Although this lack of association is contrary to previous studies demonstrating a strong relationship between SM and pain, 1, 11, 36, 37 there have been reports of asymptomatic CKCS with SM and CKCS displaying classical clinical signs without SM. 8, 20, 38, 39 In our study, we had 7 symptomatic dogs without SM and 8 asymptomatic dogs with SM.
Despite the aforementioned pitfalls, we did see a correlation between the presence of pain on neurological examination and decreased mechanical thresholds. Furthermore, neck mechanical testing data were evenly distributed in a population of dogs displaying a wide range of clinical signs. In this manner, the mechanical thresholds determined using our methodology (instrumented forceps) appear to be capturing owner and clinician observations of signs in a more quantitative fashion. These findings may be somewhat limited by individual dog personality type. It is possible that some dogs were more likely to respond to both neck palpation and mechanical thresholds because of distinct personality characteristics rather than sensory abnormalities.
In summary, the purpose of our study was to quantify sensory thresholds in a cohort of CKCS with and without SM. We found no correlation between sensory thresholds (quantified by mechanical thresholds, thermal latencies and mechanical and thermal response rates) and SM. However, the presence or absence of pain on neurological examination did correlate with mechanical thresholds. These tools may be useful for assessing sensory changes in a clinical trial setting. Because of the inconsistencies between the presence and severity of SM and QST data, the relationship between SM and clinical signs deserves further examination.
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